A medical device made by Boston Scientific of Natick that’s used to treat severe forms of asthma has been shown to be safe and effective, according to data published online in a medical journal.
The Journal of Allergy and Clinical Immunology, the official scientific journal of the American Academy of Allergy, Asthma & Immunology (AAAAI) and the most-cited journal in the field of allergy and clinical immunology, featured data from a clinical trial that examined the safety and effectiveness of Boston Scientific’s Alair Bronchial Thermoplasty (BT) System. The long-term data are based on a study of BT-treated patients from the trial who were followed for five years.
Boston Scientific announced the results today.
Key findings from the trial include:
- Reduction in the percentage of BT-treated patients experiencing severe worsening of their conditions;
- Over five years, an 88-percent average decrease observed in the rate of emergency room visits for respiratory symptoms in BT-treated patients compared to the year prior to receiving BT therapy;
- No increase in hospitalizations for respiratory symptoms; and
- No increase in adverse respiratory events.
Read more
Boston Scientific Sued Over Pacemaker Deal, Settles Patent Suit
